Page 5 - Evaluate Pharma News Today

This article discusses quantifiable market trends, clinical developments, regulatory landscape analysis, and investment trends for cell and gene...

Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals that compensate

By David Carnevali (Reuters) - Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in ...

A roller-coaster year has sent a lot of deserving names into bargain territory. Here are nine value stocks for investors to consider as we head into 2023.

New World Preview report finds strong top-line growth as pricing and patent headwinds build London, UK and Boston, MA – 18 October 2022: The global pharmaceutical industry is set to see sales grow by an annualised 6% between 2022 and 2028, according to the latest World Preview published by Evaluate Ltd...

GSK stock has endured a torrid year-to-date - down 21% in a sector that is performing much better than the S&P. Click here to read my analysis of GSK stock.

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to ...

In this article we look at why Billionaire Jeffrey Talpins Just Fled From These 10 Healthcare Stocks.

What else do these companies have in store?

The life sciences industry is facing a significant slowdown due to patent expirations. Many organizations have not established a robust enough...